Arcutis Biotherapeutics Inc
NASDAQ:ARQT
Intrinsic Value
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. [ Read More ]
The intrinsic value of one
ARQT
stock under the Base Case scenario is
11.81
USD.
Compared to the current market price of 8.59 USD,
Arcutis Biotherapeutics Inc
is
Undervalued by 27%.
Arcutis Biotherapeutics Inc's market capitalization is 987.6m USD.
ARQT stock price is 8.59 USD.
ARQT stock price (8.59 USD) is 27% less than its Intrinsic Value (11.81 USD).
ARQT. Open DCF Valuation
ARQT stock price (8.59 USD) is 27% less than its Relative Value (11.81 USD). Open Relative Valuation
ARQT has upside potential of 114% compared to the average analyst price target.
Open Wall St Estimates
ARQT's long-term assets (341m USD) exceed its long-term liabilties (253m USD).
ARQT has negative Net Debt. This means that the company has more cash and short-term investments (272m USD) than debt (202m USD).
ARQT's Revenue has grown by an exceptional 1 515% over the past 12 months.
ARQT's ROE (Return on Equity) has significantly decreased in the last 3 years from -41% to -176%, and is approaching profitability.
ARQT's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -1 216% to -551%, and is approaching profitability.
ARQT has positive Gross Profit for the last twelve months.
ARQT's D/E (Debt to Equity) is very high and is equal to 2.28.
ARQT has negative Operating Income for the last twelve months.
ARQT has negative Net Income for the last twelve months.
ARQT's ROE (Return on Equity) for the past 12 months is negative and is equal to -176%.
ARQT's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -551%.
ARQT's Revenue is forecast to grow at a rate of 84% per year over the next 3 years.
ARQT has negative Free Cash Flow for the last twelve months.
ARQT has negative three-year average ROE (Return on Equity): -109%. The company is not efficient at transforming stockholders' equity into net income.
ARQT has negative three-year average ROIC (Return on Invested Capital): -1 479%. The company is not efficient at using invested capital to generate operating income.
ARQT's short-term assets (330m USD) exceed its short-term liabilties (47m USD).
ARQT's Altman Z-Score is very low and is equal to -5.26.
ARQT doesn't generate enough operating income (-241m USD) to safely cover interest payments on its debt (25m USD).
Valuation Backtest
Arcutis Biotherapeutics Inc
Run backtest to discover the historical profit from buying and selling
ARQT
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Arcutis Biotherapeutics Inc
Balance Sheet Decomposition
Arcutis Biotherapeutics Inc
| Current Assets | 330.4m |
| Cash & Short-Term Investments | 271.9m |
| Receivables | 25.8m |
| Other Current Assets | 32.8m |
| Non-Current Assets | 10.9m |
| PP&E | 3.9m |
| Intangibles | 6.4m |
| Other Non-Current Assets | 596k |
| Current Liabilities | 46.7m |
| Accounts Payable | 12m |
| Accrued Liabilities | 34.7m |
| Non-Current Liabilities | 206m |
| Long-Term Debt | 201.8m |
| Other Non-Current Liabilities | 4.2m |
Earnings Waterfall
Arcutis Biotherapeutics Inc
|
Revenue
|
59.6m
USD
|
|
Cost of Revenue
|
-5m
USD
|
|
Gross Profit
|
54.6m
USD
|
|
Operating Expenses
|
-295.7m
USD
|
|
Operating Income
|
-241.1m
USD
|
|
Other Expenses
|
-21m
USD
|
|
Net Income
|
-262.1m
USD
|
Free Cash Flow Analysis
Arcutis Biotherapeutics Inc
ARQT Profitability Score
Profitability Due Diligence
Arcutis Biotherapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Arcutis Biotherapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
ARQT Solvency Score
Solvency Due Diligence
Arcutis Biotherapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Arcutis Biotherapeutics Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARQT Price Targets Summary
Arcutis Biotherapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ARQT
is 18.36 USD
with a low forecast of 11.11 USD and a high forecast of 27.3 USD.
Ownership
ARQT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ARQT Price
Arcutis Biotherapeutics Inc
| Average Annual Return | -8.2% |
| Standard Deviation of Annual Returns | 34.35% |
| Max Drawdown | -95% |
| Market Capitalization | 987.6m USD |
| Shares Outstanding | 114 971 000 |
| Percentage of Shares Shorted | 20.2% |
Company Profile
Arcutis Biotherapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. The company is headquartered in Westlake Village, California and currently employs 147 full-time employees. The company went IPO on 2020-01-31. The company is focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. The company harnesses its dermatology development platform to build therapies against biologically validated targets. Its dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions. The company’s lead program, topical roflumilast, has the potential to advance the care for plaque psoriasis of the body and scalp, atopic dermatitis and seborrheic dermatitis. The company is developing roflumilast cream for the treatment of plaque psoriasis, including psoriasis in intertriginous regions, such as the groin, axillae and inframammary areas, as well as atopic dermatitis. The company is also developing ARQ-252 is topical cream formulation of a potent and selective small molecule inhibitor of JAK1 and is developing it for chronic hand eczema and vitiligo.
Contact
IPO
Employees
Officers
The intrinsic value of one
ARQT
stock under the Base Case scenario is
11.81
USD.
Compared to the current market price of 8.59 USD,
Arcutis Biotherapeutics Inc
is
Undervalued by 27%.
You don't have any saved screeners yet
